公开(公告)号：US20100220987A1

公开(公告)日：2010-09-02

申请号：US11997507

申请日：2006-07-14

申请人： Akihiko Kato ,  Norihiko Kikuchi ,  Takashi Kusakari

发明人： Akihiko Kato ,  Norihiko Kikuchi ,  Takashi Kusakari

IPC分类号： G03B3/10

CPC分类号： G02B7/08 ,  H04N5/23212

摘要： It is an object of the present invention to provide an imaging device that can be reduced in production cost in comparison with the conventional imaging device, and a portable terminal provided with the imaging device. The imaging device 10 comprises a lens 11 for focusing light from an object, a magnet 12 attached to the lens 11, lens moving means 13 for moving the lens 11 along an optical axis of the lens 11, a hall element 14 for detecting a magnetic flax generated by the magnet 12, a constant current circuit 15 for driving the hall element 14, an amplifier 16 for amplifying an output voltage of the hall element 14, a comparator 17 for comparing a reference voltage with the output voltage of the hall element 14, a PWM signal producing unit 18 for producing a pulse width modulation signal, a lens controller 19 for outputting a control signal to the lens moving means 13 to control the lens moving means 13, and a lens driver 20 for driving the lens moving means 13.

摘要翻译： 本发明的目的是提供一种与传统的成像装置相比可以降低制造成本的成像装置，以及设置有成像装置的便携式终端。 成像装置10包括用于聚焦来自物体的光的透镜11，附接到透镜11的磁体12，用于沿着透镜11的光轴移动透镜11的透镜移动装置13，用于检测磁性的霍尔元件14 由磁体12产生的亚麻，用于驱动霍尔元件14的恒流电路15，放大霍尔元件14的输出电压的放大器16，将参考电压与霍尔元件14的输出电压进行比较的比较器17 ，用于产生脉宽调制信号的PWM信号产生单元18，用于向透镜移动装置13输出控制信号以控制透镜移动装置13的透镜控制器19和用于驱动透镜移动装置13的透镜驱动器20 。

公开(公告)号：US07795236B2

公开(公告)日：2010-09-14

申请号：US11717741

申请日：2007-03-13

申请人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

发明人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H19/00 ,  C07H19/16

CPC分类号： A61K45/06 ,  A61K31/7076 ,  C07H19/167 ,  C07H19/173

摘要： The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like.In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

摘要翻译： 本发明提供了可用于与血浆尿酸水平异常相关的疾病的8-修饰的嘌呤核苷衍生物。 由下式（I）表示的8-修饰的嘌呤核苷衍生物，其前体药物或其药学上可接受的盐或其水合物或溶剂合物可用于预防或治疗痛风，高尿酸血症，尿结石病，高尿酸性肾病或 类似。 在该式中，n为1或2; RA是氢原子或羟基; R1是氢原子，羟基，硫醇基，氨基或氯原子; 环J表示任选取代的2-萘基，或由以下通式（II）表示的基团，其中Y表示单键或连接基团; 环Z表示任选取代的芳基或杂芳基等; R2和R4，P1和Q表示卤原子，氰基等。

公开(公告)号：US20060082040A1

公开(公告)日：2006-04-20

申请号：US10541331

申请日：2004-10-04

申请人： Satoshi Shimizu ,  Norihiko Kikuchi ,  Tatsushi Yurudume ,  Hisao Hoshino ,  Takao Minagawa ,  Hiroyuki Osaka ,  Makoto Noudou ,  Shigeki Kishihara ,  Shingo Shikuwa

发明人： Satoshi Shimizu ,  Norihiko Kikuchi ,  Tatsushi Yurudume ,  Hisao Hoshino ,  Takao Minagawa ,  Hiroyuki Osaka ,  Makoto Noudou ,  Shigeki Kishihara ,  Shingo Shikuwa

IPC分类号： B23Q3/02

CPC分类号： C21D1/42 ,  C21D1/09 ,  C21D1/673 ,  C21D9/0025 ,  C21D9/0068 ,  Y02P10/253

摘要： A heat treatment operation can be executed, suppressing a wave-shaped deformation at a non heat-treatment region of an article to be heat treated. To an elongated-shaped article to be heat treated (10) to which a raised portion (11) extending in the longitudinal direction is formed, a hardening region as being a heat-treated region defined to be extended in a longitudinal direction at a part of the raised portion (11) and a non-hardening region as being non heat-treated region defined to be extended in the longitudinal direction at flange portion (13) and other parts of the raised portion (11) are arranged side by side in a width direction orthogonal to the longitudinal direction. The flange portion (13) is clamped by a first and a second clamping means (22), (23) arranged in the longitudinal direction, and one first clamping means (22) is a tight clamping means holding fixedly the flange portion (13) and a plurality of second clamping means (23) are loose clamping means clamping loosely the flange portion (13), allowing the article to be heat treated (10) to be convex on the side of the heated hardening region.

摘要翻译： 可以进行热处理操作，抑制待热处理物品的非热处理区域的波状变形。 对于形成有沿长度方向延伸的凸部（11）进行热处理的细长型制品（10），形成作为热处理区域的硬化区域，其被定义为在纵向方向上延伸的部分 的突出部（11）的非热硬化区域和非凸部（11）的其他部分在长度方向上被限定为非热处理区域的非硬化区域并排配置在 与纵向正交的宽度方向。 凸缘部分（13）由沿纵向布置的第一和第二夹紧装置（22），（23）夹持，一个第一夹紧装置（22）是固定地保持凸缘部分（13）的紧固装置， 并且多个第二夹紧装置（23）是松弛地夹紧凸缘部分（13）的松紧夹紧装置，允许制品在加热硬化区域一侧被热处理（10）凸起。

公开(公告)号：US08466152B2

公开(公告)日：2013-06-18

申请号：US13116389

申请日：2011-05-26

申请人： Kazuo Shimizu ,  Yasushi Takigawa ,  Hideki Fujikura ,  Masato Iizuka ,  Masahiro Hiratochi ,  Norihiko Kikuchi

发明人： Kazuo Shimizu ,  Yasushi Takigawa ,  Hideki Fujikura ,  Masato Iizuka ,  Masahiro Hiratochi ,  Norihiko Kikuchi

IPC分类号： A61K31/404 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/519 ,  C07D209/10 ,  C07D209/30 ,  C07D209/42 ,  C07D471/04 ,  C07D487/14

CPC分类号： C07D209/30 ,  A61K31/165 ,  A61K31/404 ,  A61K31/407 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/42 ,  C07D401/04 ,  C07D405/04 ,  C07D405/10 ,  C07D409/12 ,  C07D417/04 ,  C07D471/04 ,  C07D491/056 ,  A61K2300/00

摘要： The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, —N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

摘要翻译： 本发明提供可用作预防或治疗与具有尿酸活性等的异常血清尿酸水平相关的疾病的药剂的化合物。 本发明涉及具有黄嘌呤氧化酶抑制活性的由以下通式（I）表示的（aza）吲哚衍生物，可用作预防或治疗与血清尿酸水平异常有关的疾病，其前药或盐 其中。 在式（I）中，T表示硝基或氰基等; 环J表示芳基或杂芳基等; Q表示羧基或5-四唑基等; Y表示H，OH，NH 2，卤素，硝基，烷基，烷氧基等; X1，X2和X3独立地表示CR2或N; R 1和R 2独立地表示卤素，氰基，卤代烷基，A-D-E-G，-N（-D-E-G）2等，式中，A表示单键O，S等; D和G独立地表示任选取代的亚烷基，亚环烷基，亚杂环亚烷基，亚芳基，杂亚芳基等; E表示单键O，S，COO，SO 2等。

公开(公告)号：US08003647B2

公开(公告)日：2011-08-23

申请号：US12595476

申请日：2008-04-10

申请人： Kazuo Shimizu ,  Yasushi Takigawa ,  Hideki Fujikura ,  Masato Iizuka ,  Masahiro Hiratochi ,  Norihiko Kikuchi

发明人： Kazuo Shimizu ,  Yasushi Takigawa ,  Hideki Fujikura ,  Masato Iizuka ,  Masahiro Hiratochi ,  Norihiko Kikuchi

IPC分类号： A61K31/404 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/519 ,  C07D209/10 ,  C07D209/30 ,  C07D209/42 ,  C07D471/04 ,  C07D487/14

CPC分类号： C07D209/30 ,  A61K31/165 ,  A61K31/404 ,  A61K31/407 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/42 ,  C07D401/04 ,  C07D405/04 ,  C07D405/10 ,  C07D409/12 ,  C07D417/04 ,  C07D471/04 ,  C07D491/056 ,  A61K2300/00

摘要： The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetrazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, —N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

摘要翻译： 本发明提供可用作预防或治疗与具有尿酸活性等的异常血清尿酸水平相关的疾病的药剂的化合物。 本发明涉及具有黄嘌呤氧化酶抑制活性的由以下通式（I）表示的（aza）吲哚衍生物，可用作预防或治疗与血清尿酸水平异常有关的疾病，其前药或盐 其中。 在式（I）中，T表示硝基或氰基等; 环J表示芳基或杂芳基等; Q表示羧基或5-四唑基等; Y表示H，OH，NH 2，卤素，硝基，烷基，烷氧基等; X1，X2和X3独立地表示CR2或N; R 1和R 2独立地表示卤素，氰基，卤代烷基，A-D-E-G，-N（-D-E-G）2等，式中，A表示单键O，S等; D和G独立地表示任选取代的亚烷基，亚环烷基，亚杂环亚烷基，亚芳基，杂亚芳基等; E表示单键O，S，COO，SO 2等。

公开(公告)号：US07576064B2

公开(公告)日：2009-08-18

申请号：US10561217

申请日：2004-06-15

申请人： Norihiko Kikuchi ,  Hideki Fujikura ,  Shigeki Tazawa ,  Tokuhisa Yamato ,  Masayuki Isaji

发明人： Norihiko Kikuchi ,  Hideki Fujikura ,  Shigeki Tazawa ,  Tokuhisa Yamato ,  Masayuki Isaji

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H17/00

CPC分类号： C07D231/32 ,  A61K31/7056 ,  A61K31/706 ,  C07D231/52 ,  Y10S514/866

摘要： The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl, etc.; one of Q and T represents a group selected from the following: and the other represents -Z-Ar wherein Z represents —O—, —S—, etc.; Ar represents an optionally substituted C6-10 aryl, etc.; R represents an optionally substituted C3-8 cycloalkyl, an optionally substituted C6-10 aryl, etc., pharmaceutically acceptable salts thereof, and prodrugs thereof, which exhibit an excellent inhibitory activity in human sodium/glucose cotransporter (SGLT) and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose (diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, etc.), and pharmaceutical compositions containing the same, medicinal uses thereof and intermediates for production therefor.

摘要翻译： 本发明提供由以下通式表示的吡唑衍生物：其中R1表示H，任选取代的C 1-6烷基等; Q和T中的一个表示选自以下的基团：另一个表示-Z-Ar，其中Z表示-O-，-S-等; Ar表示任选取代的C 6-10芳基等。 R表示在人钠/葡萄糖共转运体（SGLT）中表现出优异抑制活性的可任选取代的C 3-8环烷基，任选取代的C 6-10芳基等，其药学上可接受的盐及其前药，并且可用作试剂 用于预防，抑制与选自葡萄糖，果糖和甘露糖（糖尿病，餐后高血糖，葡萄糖耐量降低，糖尿病并发症等）中的至少一种碳水化合物的过量摄取相关的疾病的进展或治疗，以及药物 含有该组合物的组合物，其医药用途和用于其生产的中间体。

公开(公告)号：US07576063B2

公开(公告)日：2009-08-18

申请号：US10529895

申请日：2003-09-30

申请人： Hideki Fujikura ,  Norihiko Kikuchi ,  Shigeki Tazawa ,  Tokuhisa Yamato ,  Masayuki Isaji

发明人： Hideki Fujikura ,  Norihiko Kikuchi ,  Shigeki Tazawa ,  Tokuhisa Yamato ,  Masayuki Isaji

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H17/00

CPC分类号： C07D405/04 ,  A61K31/7056 ,  C07D231/20 ,  C07D401/04 ,  C07D409/04 ,  C07H17/02 ,  Y10S514/866

摘要： The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group selected from the following groups: and the other represents —(CH2)n—Ar wherein Ar represents an optionally substituted C6-10 aryl group or an optionally substituted C1-9 heteroaryl group; and n represents an integral number from 0 to 2, an optionally substituted C1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C2-9 heterocycloalkyl group or an optionally substituted heterocycle-fused phenyl group; R represents an optionally substituted C3-8 cycloalkyl group, an optionally substituted C6-10 aryl group etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human 1,5-anhydroglucitol/fructose/mannose transporter and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose or a disease associated with hyperglycemia (e.g., diabetic complications, diabetes, etc.), and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

摘要翻译： 本发明提供由以下通式表示的吡唑衍生物：其中R1表示H，任选取代的C 1-6烷基等; Q和T之一表示选自以下基团的基团：另一个表示 - （CH 2）n -Ar，其中Ar表示任选取代的C 6-10芳基或任选取代的C 1-8杂芳基; n表示0〜2的整数，可以具有取代基的C 1-6烷氧基，可以具有取代基的氨基，可以具有取代基的C2-9杂环烷基或任意取代的杂环稠合苯基; R表示任选取代的C 3-8环烷基，任选取代的C 6-10芳基等，其药学上可接受的盐或其前体药物，其在人1,5-脱水葡萄糖醇/果糖/甘露糖转运蛋白中表现出优异的抑制活性， 可用作预防，抑制与选自葡萄糖，果糖和甘露糖中的至少一种碳水化合物或与高血糖相关疾病（例如，糖尿病并发症，糖尿病等）的过量摄取相关疾病进展或治疗的药剂。 ），以及包含该药物组合物的药物组合物，其药学用途及其生产用中间体。

公开(公告)号：US20080139484A1

公开(公告)日：2008-06-12

申请号：US11576204

申请日：2005-09-28

申请人： Hirotaka Teranishi ,  Norihiko Kikuchi ,  Kohsuke Ohno

发明人： Hirotaka Teranishi ,  Norihiko Kikuchi ,  Kohsuke Ohno

IPC分类号： A61K31/7056 ,  C07H17/02 ,  A61P3/10 ,  A61P3/06 ,  A61P3/00

CPC分类号： A61K31/7056 ,  A61K31/706 ,  A61K45/06 ,  C07H19/04 ,  A61K2300/00

摘要： A compound having SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-(β-D-glycopyranosyl)-3-substituted nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a medicinal use thereof. In the formula, ring A represents optionally substituted aryl or heteroaryl; Q1 to Q5 independently represent a carbon atom having a hydrogen atom or substituent bonded thereto or a nitrogen atom; E represents a single bond, alkylene, —O—, —S— or —NH—; and R represents methyl, ethyl, fluoromethyl or hydroxymethyl.

摘要翻译： 具有SGLT1和/或SGLT2抑制活性的化合物，其可用作预防或治疗糖尿病，餐后高血糖症，葡萄糖耐量降低，糖尿病并发症，肥胖症等的药物。它是1-（β-D-糖吡喃糖基） 由通式（I）表示的3-取代的含氮杂环化合物，其前体药物或其药学上可接受的盐，或其水合物或溶剂化物; 含有其的SGLT抑制剂; 含有该组合物的药物组合物及其药物用途。 在该式中，环A表示任选取代的芳基或杂芳基; Q 1至Q 5独立地表示具有与其键合的氢原子或取代基的碳原子或氮原子; E表示单键，亚烷基，-O - ， - S-或-NH-; R代表甲基，乙基，氟甲基或羟甲基。

公开(公告)号：US07361015B2

公开(公告)日：2008-04-22

申请号：US10541331

申请日：2004-10-04

申请人： Satoshi Shimizu ,  Norihiko Kikuchi ,  Tatsushi Yurudume ,  Hisao Hoshino ,  Takao Minagawa ,  Hiroyuki Osaka ,  Makoto Noudou ,  Shigeki Kishihara ,  Shingo Shikuwa

发明人： Satoshi Shimizu ,  Norihiko Kikuchi ,  Tatsushi Yurudume ,  Hisao Hoshino ,  Takao Minagawa ,  Hiroyuki Osaka ,  Makoto Noudou ,  Shigeki Kishihara ,  Shingo Shikuwa

IPC分类号： F27D5/00

CPC分类号： C21D1/42 ,  C21D1/09 ,  C21D1/673 ,  C21D9/0025 ,  C21D9/0068 ,  Y02P10/253

摘要： A heat treatment operation can be executed, suppressing a wave-shaped deformation at a non heat-treatment region of an article to be heat treated.To an elongated-shaped article to be heat treated to which a raised portion extending in the longitudinal direction is formed, a hardening region, as a heat-treated region defined to extend in a longitudinal direction at a part of the raised portion, and a non-hardening region, as a non-heat-treated region defined to extend in the longitudinal direction at flange portion, and other parts of the raised portion are arranged side by side in a width direction orthogonal to the longitudinal direction. The flange portion is clamped by a first and a second clamp, arranged in the longitudinal direction, and one first clamp is a tight clamp for holding fixedly the flange portion and a plurality of second clamps are loose clamps for clamping loosely the flange portion, allowing the article to be heat treated to be convex on the side of the heated hardening region.

摘要翻译： 可以进行热处理操作，抑制待热处理物品的非热处理区域的波状变形。 对于形成有沿长度方向延伸的凸起部的被热处理的细长型制品，作为被确定为在凸部的一部分沿长度方向延伸的热处理区域的硬化区域，以及 非硬化区域，被定义为在凸缘部分沿长度方向延伸的非热处理区域，并且凸起部分的其它部分在与纵向正交的宽度方向上并排布置。 凸缘部分由沿纵向方向布置的第一和第二夹具夹紧，一个第一夹具是用于固定凸缘部分的紧固夹具，并且多个第二夹具是用于松动地夹紧凸缘部分的松紧夹具，允许 待热处理的制品在加热的硬化区域的一侧凸出。

公开(公告)号：US20070179115A1

公开(公告)日：2007-08-02

申请号：US11717741

申请日：2007-03-13

申请人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

发明人： Kazuya Tatani ,  Yoshinori Nonaka ,  Norihiko Kikuchi

IPC分类号： A61K31/7076 ,  C07H19/16

CPC分类号： A61K45/06 ,  A61K31/7076 ,  C07H19/167 ,  C07H19/173

摘要： The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

摘要翻译： 本发明提供了可用于与血浆尿酸水平异常相关的疾病的8-修饰的嘌呤核苷衍生物。 由下式（I）表示的8-修饰的嘌呤核苷衍生物，其前体药物或其药学上可接受的盐或其水合物或溶剂合物可用于预防或治疗痛风，高尿酸血症，尿结石病，高尿酸性肾病或 类似。 在该式中，n为1或2; R A是氢原子或羟基; R 1是氢原子，羟基，硫醇基，氨基或氯原子; 环J表示任选取代的2-萘基，或由以下通式（II）表示的基团，其中Y表示单键或连接基团; 环Z表示任选取代的芳基或杂芳基等; R 2〜R 4，P 1和Q表示卤素原子，氰基等。